FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to use of a compound of formula III, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvate for treating AR+/ER+ breast cancer in a subject.
EFFECT: treatment of AR+/ER+ breast cancer.
34 cl, 8 dwg, 3 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR TREATING CANCER | 2021 |
|
RU2833058C1 |
| METHODS OF TREATING CANCER | 2016 |
|
RU2737496C2 |
| OESTROGEN RECEPTOR MODULATING COMPOUNDS | 2020 |
|
RU2833430C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
